

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Nanjing Leads Biolabs Co., Ltd.**  
**南京维立志博生物科技股份有限公司**

*(A joint stock company established in the People's Republic of China with limited liability)*

**(Stock Code: 9887)**

**AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the announcement of our Company dated July 24, 2025 in relation to the final offer price and allotment results in respect of the listing of an aggregate of 36,862,500 H Shares on the Main Board of the Hong Kong Stock Exchange and the announcement dated August 7, 2025 in relation to the full exercise of the Over-allotment Option in respect of an aggregate of 5,529,300 H Shares, representing approximately 15% of the total number of the Offer Shares available under the Global Offering (after taking into account the full exercise of the Offer Size Adjustment Option but before any exercise of the Over-allotment Option) (together, the “**Announcements**”). Unless the context otherwise requires, terms used herein shall have the same meanings as those defined in the Announcements.

Upon completion of full exercise of the Over-allotment Option, the registered share capital and total number of the shares of the Company were changed to RMB198,891,800 and 198,891,800 shares, respectively. To reflect such changes in the registered share capital and share capital structure of the Company, corresponding amendments were made to the articles of association of the Company (the “**Articles of Association**”).

Pursuant to the authorization granted at the 2024 third extraordinary general meeting on October 25, 2024, and further authorization granted by the board of directors of the Company (the “**Board**”), the persons authorized by the Board have approved to make corresponding adjustments and amendments to the Articles of Association based on the completion of the Global Offering, including but not limited to the amendments to the registered share capital and total number of issued shares of the Company.

Particulars of the amendments to the Articles of Association are as follows:

Original articles	Amended articles
<b>Article 3</b> The Company completed the filing with the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) on May 30, 2025 and was listed on the main board of the Stock Exchange of Hong Kong Limited (hereinafter referred to as the “Hong Kong Stock Exchange”) on [•••].	<b>Article 3</b> The Company completed the filing with the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) on May 30, 2025 and was listed on the main board of the Stock Exchange of Hong Kong Limited (hereinafter referred to as the “Hong Kong Stock Exchange”) on <del>[•••]</del> <u>July 25, 2025</u> .
<b>Article 6</b> The registered capital of the Company: RMB[•••].	<b>Article 6</b> The registered capital of the Company: RMB <del>[•••]</del> <u>198,891,800</u> .
<b>Article 22</b> The total number of shares of the Company is [•••], all of which are ordinary shares.	<b>Article 22</b> The total number of shares of the Company is <del>[•••]</del> <u>198,891,800</u> , all of which are ordinary shares.
<b>Article 23</b> Following the completion of the initial public offering of H shares, assuming the over-allotment option is not exercised, the share capital structure of the Company on the listing date will consist of [•••] ordinary shares, comprising [•••] unlisted shares and [•••] H shares; assuming the over-allotment option is exercised in full, the share capital structure of the Company will consist of [•••] ordinary shares, comprising [•••] unlisted shares and [•••] H shares.	<del><b>Article 23</b> Following the completion of the initial public offering of H shares, assuming the over-allotment option is not exercised, the share capital structure of the Company on the listing date will consist of [•••] ordinary shares, comprising [•••] unlisted shares and [•••] H shares; assuming the over-allotment option is exercised in full, the share capital structure of the Company will consist of [•••] ordinary shares, comprising [•••] unlisted shares and [•••] H shares.</del> <b>Article 23</b> Following the completion of the initial public offering of H shares, assuming the over-allotment option is exercised in full, the share capital structure of the Company will consist of <del>[•••]</del> <u>198,891,800</u> ordinary shares, comprising <del>[•••]</del> <u>45,613,109</u> unlisted shares and <del>[•••]</del> <u>153,278,691</u> H shares.

The industrial and commercial registration, filing and other matters in respect of the above amendments to the Articles of Association with the relevant government or regulatory authorities in the PRC will be completed. The full text of the amended Articles of Association is available on the website of The Stock Exchange of Hong Kong Limited ([www.hkexnews.hk](http://www.hkexnews.hk)) and the website of the Company ([www.leadsbiolabs.com](http://www.leadsbiolabs.com)).

By order of the Board  
**Nanjing Leads Biolabs Co., Ltd.**  
南京维立志博生物科技股份有限公司  
**Dr. KANG XIAOQIANG**  
*Chairman, Executive Director and  
Chief Executive Officer*

Nanjing, PRC, September 17, 2025

*As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Ni Jia as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive directors.*